Myriad Updates: Clinical Data as Trade Secrets and a Pending Certiorari Decision
By Dan Vorhaus,
Genomics Law Report
| 11. 28. 2012
Earlier this month, my colleagues John Conley, Robert Cook-Deegan, James Evans and I published a policy article in the
European Journal of Human Genetics (EJHG) entitled “
The next controversy in genetic testing: clinical data as trade secrets.”
The EJHG article is open access so you can read the
entire article at the EJHG website, but here is the abstract:
Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services; establishing – and compelling participation in – resources that capture the information needed to interpret the data...
Related Articles
By Holly Baxter, The Independent | 08.19.2025
In rural Pennsylvania, I’m hiking through the forest with Simone and Malcom Collins and discussing the executive order they wrote for Donald Trump. Just outside their house — beyond the chicken coop, where they gather their eggs for homemade cakes...
By Jacob Bogage, The Washington Post | 09.03.2025
The conservative group behind the Project 2025 governing playbook for President Donald Trump’s second term is set to propose sweeping revisions to U.S. economic policy meant to encourage married heterosexual couples to have more children.
The Heritage Foundation, a right-wing...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Tia Ghose, Live Science | 09.16.2025
Twenty-six years ago today, on Sept. 17, a teenager who had received an experimental gene therapy died. His death led to needed changes in the clinical trial process while also spurring skepticism that would ultimately stall the field of gene...